Camlin Fine Sciences

Tariff Benefits And Safety Trends Will Boost US And Europe

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

04 Sep 25

Updated

26 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

24.9%

-5.9%

24.9%

-5.9%

You can edit this narrative until Nov 27 4:25 AM. Then, changes will post as Updates.

Author's Valuation

₹24036.7% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 26 Nov 25

Fair value Decreased 11%

532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns

Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.

Shared on 11 Nov 25

Fair value Decreased 8.47%

532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure

Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.

AnalystConsensusTarget Fair Value

₹240

36.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

19.34%

Chemicals revenue growth rate

0.61%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

14.00%

Calculation

₹2.75b

Earnings '28

29.43x

PE Ratio '28

₹81.07b

Market Cap '28

₹81.07b

Market Cap '28

237.88m

No. shares '28

₹340.81

Share Price '28

₹340.81 Share Price '28

Discounted to 2025 @ 14.00% p.a.

₹230.03

Fair Value '25